# Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

> **NCT02268214** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 833 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo for dapagliflozin

## Key facts

- **NCT ID:** NCT02268214
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-11
- **Primary completion:** 2017-01-04
- **Final completion:** 2017-08-25
- **Target enrollment:** 833 (ACTUAL)
- **Last updated:** 2018-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268214, "Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02268214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*